Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
November 2025
Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: A multicentre, randomised, double-blind, placebo-controlled trial
Ann Rheum Dis 2025 Doi: 10.1016/j.ard.2025.10.010. Epub ahead of print
Sun et al. provides the first RCT evidence that low-dose belimumab reduces flares in patients with SLE with low-grade disease activity. Authors evaluated the efficacy of low-dose belimumab for disease flare prevention in Chinese patients with low-grade SLE (SELENA-SLEDAI ≤6).
Keywords:
August 2025
Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: A randomised, double-blind, placebo-controlled, Phase II study
RMD Open 2025;11:e005557 Doi:10.1136/rmdopen-2025-005557
Shen N et al. report that iscalimab was clinically effective and generally well tolerated; in addition, it was devoid of the thromboembolic risk, characteristic of Fc active anti-CD40L therapies.